Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

HAEMATOLOGICAL CANCER

Anti-CD19 CAR T cell therapy for lymphoma — off to the races!

Nature Reviews Clinical Oncology volume 16, pages 279–280 (2019)Cite this article

Subjects

Recently published data from the ZUMA-1 and JULIET trials suggest that CD19-directed chimeric antigen receptor (CAR) T cell therapy can provide durable remissions, with a low risk of relapse or progression, in 30–40% of patients with relapsed and/or refractory aggressive large B cell lymphoma. Two-year follow-up of the ZUMA-1 clinical trial has not revealed any unexpected toxicities, but further safety monitoring will be needed.

Refers to Locke, F. L. et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol. 20, 31–427 (2019) | Schuster, S. J. et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 380, 45–56 (2019).

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

References

  1. Locke, F. L. et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol. 20, 31–42 (2019).

    CAS  Article  Google Scholar 

  2. Schuster, S. J. et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 380, 45–56 (2019).

    CAS  Article  Google Scholar 

  3. Crump, M. et al. Outcomes in refractory diffuse large B cell lymphoma: results from the international SCHOLAR-1 study. Blood 130, 1800–1808 (2017).

    CAS  Article  Google Scholar 

  4. Salter, A. I. et al. Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function. Sci. Signal. 11, eaat6753 (2018).

    Article  Google Scholar 

  5. Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T cell therapy in refractory large B cell lymphoma. N. Engl. J. Med. 377, 2531–2544 (2017).

    CAS  Article  Google Scholar 

  6. Lee, D. W. et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124, 188–195 (2014).

    CAS  Article  Google Scholar 

  7. Schuster, S. J. et al. Consensus grading of cytokine release syndrome (CRS) in adult patients with relapsed or refractory diffuse large B cell lymphoma (r/rDLBCL) treated with tisagenlecleucel on the JULIET study [abstract 4190]. Presented at the 60th ASH Annual Meeting and Exposition in San Diego, CA (2018).

  8. Locke, F. L. et al. Durability of response in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-cel) in patients (Pts) with refractory large B cell lymphoma. J. Clin. Oncol. 36 (Suppl. 15), 3003 (2018).

    Article  Google Scholar 

  9. Lee, D. W. et al. ASBMT consensus grading for cytokine release syndrome and neurological toxicity associated with immune effector cells. Biol. Blood Marrow Transplant. https://doi.org/10.1016/j.bbmt.2018.12.758 (2018).

    Article  PubMed  Google Scholar 

  10. Nastoupil, L. J. et al. Axicabtagene ciloleucel (Axi-cel) CD19 chimeric antigen receptor (CAR) T cell therapy for relapsed/refractory large B cell lymphoma: real world experience. Blood 132, 91 (2018).

    Article  Google Scholar 

  11. Abramson, J. et al. Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL. J. Clin. Oncol. 36 (Suppl. 15), 7505 (2018).

    Article  Google Scholar 

Download references

Author information

Affiliations

  1. Bezos Family Immunotherapy Clinic, Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA, USA

    David G. Maloney

Authors
  1. David G. Maloney
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David G. Maloney.

Ethics declarations

Competing interests

D.G.M. has participated in and received honoraria for clinical advisory boards for Juno/Celgene, Kite/Gilead and Novartis. The employing institution of D.G.M. receives clinical trial research support from Juno/Celgene and Kite/Gilead.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Maloney, D.G. Anti-CD19 CAR T cell therapy for lymphoma — off to the races!. Nat Rev Clin Oncol 16, 279–280 (2019). https://doi.org/10.1038/s41571-019-0183-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41571-019-0183-7

Further reading

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing